Hepatic injury associated with halogenated anaesthetics: Cross-sensitization and its clinical implications

European Journal of Anaesthesiology

Volumn 14, Issue 1, 1997, Pages 7-14

  Mikatti, N El ^a   Healy, T E J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOTHANE; INHALATION ANESTHETIC AGENT;

CROSS ALLERGY; DRUG HYPERSENSITIVITY; INHALATION ANESTHESIA; LIVER INJURY; LIVER TOXICITY; REVIEW;

EID: 0030862670     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003643-199701000-00003     Document Type: Review

References (57)

1. Koff RG. Postoperative jaundice. Surg Clin North Am 1975; 59: 823-837.
2. Kenna JG, Jones RM. The organ toxicity of inhaled anaesthetics. Anesth Analg 1995; 81: S51-66.
3. Ray DC, Drummond GB. Halothane hepatitis. Br Anaesth 1991; 67: 84-99.
4. Zimmerman H. Even isoflurane. Editorial. Hepatology 1991; 13,6: 1251-1253.
5. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Int Med 1983; 98: 984-992.
6. Eger Ei II, Smuckler EA, Ferrell LD, Goldsmith CH, Johnson BH. Is enflurane hepatotoxic? Anesth Analg 1986; 65: 21-30.
7. Allen PJ, Downing JW. A prospective study of hepatocellular function after repeated exposures to halothane or enflurane in women undergoing radium therapy for cervical cancer. Br J Anaesth 1977; 49: 1035-1039.
8. Dundee JW, Fee JPH, Mcllory PDA, Black GW. Prospective study of liver function following repeat halothane and enflurane. J Roy Soc Med 1981; 74: 286-291.
9. Paull JD, Fortune DW. Hepatotoxicity and death following two enflurane anaesthetics. Anaesthesia 1987; 42: 1191-1196.
10. Allan LG, Hussey AJ, Howie J et al. Hepatic glutathione S-transferase release after halothane anaesthesia: open randomised comparison with isoflurane. Lancet 1987; 1: 771-774.
11. Hussey AJ, Aldridge LM, Paul D, Ray DC, Beckett GJ, Allan LG. Plasma glutathione S-transferase concentration as a measure of hepatocollular integrity following a single general anaesthetic with halothane, enflurane or isoflurane. Br J Anaesth 1988; 60: 130-135.
12. Stoelting RK, Blitt CD, Cohen PJ, Merin RG. Hepatic dysfunction after isoflurane anaesthesia. Anesth Analg 1987; 66: 147-153.
13. Brown BR. Hepatotoxicity of inhalational anaesthetics. Current opinion in Anaesthesiology 1989; 2: 414-417.
14. McLaughlin DF, Eger II Ei. Repeated isoflurane anaesthesia in a patient with hepatic dysfunction. Anesth Anaig 1984; 63: 775-778.
15. Gregoire S, Smiley RK. Acute hepatitis in a patient with mild factor IX deficiency after anaesthesia with isoflurane. Can Med Assoc J 1986; 135: 645-646.
16. Carrigan TW, Straughen WJ. A report of hepatic necrosis and death following isoflurane anaesthesia. Anesthesiology 1987; 67: 581-583.
17. Brunt EM, White H, Marsh JW, Holtmann B, Peters MG. Fulminant hepatic failure after repeated exposure to isoflurane anaesthesia. A case report. Hepatology 1991; 13: 1017-1021.
18. Brown BR, Frink EJ. Status of inhalational anesthetic hepatotoxicity in the 1990s. Anesthesiology Review 1990; 17,6: 15-21.
19. Goldfarb G, Rogier E, Gebauer C et al. Comparative effects of halothane and isoflurane anaesthesia on the ultrastructure of human hepatic cells. Anesth Analg 1989; 69: 491-495.
20. Gelman S. Halothane hepatotoxicity again? Anaesth Analg 1986; 65: 831-834.
21. Gelman S, Van Dyke R. Mechanism of halothane-induced hepatotoxicity: another step on a long path. Anesthesiology 1988; 68: 479-482.
22. Neuberger JM. Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines. Drug Saf 1990 5(1): 28-38.
23. Neuberger JM, Kenna JG, Halothane hepatitis: a model of immune-mediated drug hepatotoxicity. Clin Sci 1987; 72: 263-271.
24. Kanaya N, Nakayama M, Fujita S, Watanabe H, Namiki A. The effects of halothane and isoflurane on hepatic blood flow as measured by the finger piece indocyanine green test. Anaesth Anaig 1993; 76: S1-S476.
25. Cook TL, Beppu WJ, Hitt BA, Kosek JC, Mazze RI. Renal effects and metabolism of sevoflurane in Fischer 344 rats: an in-vivo and in-vitro comparison with methoxyflurane. Anesthesiology 1975; 43: 70-77.
26. Takeda J, Kobayashi Y, Ochiai R, Sekiguchi H. Clinical survey of sevoflurane anaesthesia on hepato-renal function. Anaesth Anaig 1993; 76: S1-S476.
27. Strum DP, Eger II Ei, Johnson BH, Steffey EP, Ferrell LD. Toxicity of sevoflurane in rats. Anesth Analg 1987; 66: 769-773.
28. Lind RC, Ghantous HN, Gandolfi AJ, Brown BR. Sevoflurane biotransformation and hepatotoxicity in the guinea pig. Anesthesiology 1989; 71: A310.
29. Frink EJ. The hepatic effects of sevoflurane. Anesth Analg 1995; 81: S46-50.
30. Green Jr WB, Eckerson ML, Depa R, Brown Jr BR. Covalent binding of oxidative metabolites to hepatic protein not detectable after exposure to sevoflurane or desflurane. Anesthesiology 1994; 81: A437.
31. 2+ mobilization in rat hepatocytes. Anesthesiology 1990; 72: 504-509.
32. Blitt CD, Gandolfi AJ, Soltis JJ, Brown Jr BB. Extra-hepatic biotransformation of halothane and enflurane. Anesth Analg 1981; 60: 129-232.
33. Davidkova T, Kikuchi H, Fuji K et al. Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. Anesthesiology 1988; 69: 218-222.
34. Gil F, Fiserova-Bergerova V, Altman NH. Hepatic protection from chemical injury by isoflurane. Anesth Analg 1988; 67: 860-867.
35. Eger II Ei, Johnson BH, Strum DP, Ferrell LD. Studies of the toxicity of I-653, halothane and isoflurane in enzyme-induced hypoxic rats. Anesth Analg 1987; 66: 1227-1229.
36. Holmes AA, Weiskopf RB, Eger II Ei, Johnson BH, Rampil IJ. Hepatocellular integrity in swine after prolonged desflurane (I-653) and isoflurane anaesthesia: Evaluation of plasma alanine aminotransferase activity. Anesth Analg 1990; 71: 249-253.
37. Jones RM, Koblin JN, Cashman JN, Eger II Ei, Johnson BH, Damask MC. Biotransformation and hepato-renal function in volunteers after exposure to desflurane (1-653). Br J Anaesth 1990; 64: 482-487.
38. Pohl LR, Kenna JG, Satoh H, Christ DD, Martin JL. Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989; 20: 203-217.
39. Satoh H, Davies HW, Takemura T, Gillette JR, Maeda K, Phol LR. An immunochemical approach to investigating the mechanism of halothane-induced hepatotoxicity. In: Bridges JW, Chasseaud LF, Gibson CG, eds. Progress in Drug Metabolism. Philadelphia. Taylor and Francis, 1987: 187-206.
40. Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245: 1103-1109.
41. Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of halothane hepatitis patients are directed against a trifluoroacetylated carboxylesterase. Proc Nat Acad Sci, USA 1989; 86: 322-326.
42. Kenna JG, Neuberger J, Williams R. Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther 1987; 242: 733-740.
43. Ritchie PA, Cheshire MA, Pearce NH. Decontamination of halothane from anaesthetic machines achieved by continuous flushing with oxygen. Br J Anaesth 1988; 60: 859-863.
44. Hubbard AK, Gandolfi AJ, Brown BR. Immunological basis of anaesthetic-induced hepatotoxicity. Anesthesiology 1988; 69: 814-817.
45. Hubbard AK, Roth TP, Gandolfi AJ. Elicitation of a cell mediated immune response to a reactive intermediate of halothane. Toxicologist 1988; 8: 12.
46. Martin JL, Kenna JG, Pohl LR. Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 1990; 70: 154-159.
47. Kenna JG, Neuberger J, Williams R. An enzyme-linked immunosorbent assay for detection of antibodies against halothane-altered hepatocyte antigens. J Immunol Methods 1984; 75: 3-14.
48. Kenna JG, Neuberger J, Williams R. Specific antibodies to halothane-induced liver antigens in halothane-associated hepatitis. Br J Anaesth 1987; 59: 1286-1290.
49. Bird GLA, Williams R. Detection of antibodies to a halothane metabolite hapten in sera from patients with halothane-associated hepatitis. J Hepatol 1989; 9: 366-373.
50. Hubbard AK, Roth TP, Gandolfi AJ, Brown BR, Webster NR, Nunn JF. Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane. Anesthesiology 1988; 68: 791-796.
51. Hastings KL, Thomas C, Hubbard AK, Gandolfi AJ. Screening for antibodies associated with halothane hepatitis. Br J Anaesth 1991; 67: 722-728.
52. Christ DD, Satoh H, Kenna JG, Pohl LR. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988; 16: 135-140.
53. Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69: 833-838.
54. Rice SA, Maze M, Smith CM, Kosek JC, Mazze RI. Halothane hepatotoxicity in Fischer 344 rats pretreated with isoniazid. Toxicol Appl Pharmacol 1987; 87: 411-419.
55. Rice SA, Talcott TE. Effects of isoniazid treatment on selected hepatic mixed-function oxidase. Drug Metab Dispos 1979; 7: 260-262.
56. Rice SA, Dooley JR, Mazze RI. Metabolism by rat hepatic microsomes of fluorinated ether anesthetics following ethanol consumption. Anesthesiology 1980; 58: 237-241.
57. Favreau LV, Malchoff DM, Mole JE, Schenkman JB. Response to insulin by two forms of rat heptic microsomal cytochrome P450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J Biol Chem 1987; 262: 14319-14326.